Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Hydroxyurea.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Hydroxyurea.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Hydroxyurea.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hydroxyurea.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Hydroxyurea.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Hydroxyurea.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyurea.
Clozapine
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Hydroxyurea.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Hydroxyurea.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Hydroxyurea.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Hydroxyurea.
Didanosine
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Didanosine.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Hydroxyurea.
Digoxin
Digoxin may decrease the cardiotoxic activities of Hydroxyurea.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Hydroxyurea.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyurea.
Fingolimod
Hydroxyurea may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hepatitis B Vaccine (Recombinant).
Leflunomide
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Leflunomide.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Hydroxyurea.
Natalizumab
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Hydroxyurea.
Ouabain
Ouabain may decrease the cardiotoxic activities of Hydroxyurea.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hydroxyurea.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyurea.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydroxyurea.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Hydroxyurea.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydroxyurea.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Hydroxyurea.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydroxyurea.
Stavudine
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Stavudine.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Hydroxyurea.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Hydroxyurea.
Tofacitinib
Hydroxyurea may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Hydroxyurea.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Yellow Fever Vaccine.
